These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Erythropoietin attenuates renal and pulmonary injury in polymicrobial induced-sepsis through EPO-R, VEGF and VEGF-R2 modulation. Heitrich M; García DM; Stoyanoff TR; Rodríguez JP; Todaro JS; Aguirre MV Biomed Pharmacother; 2016 Aug; 82():606-13. PubMed ID: 27470403 [TBL] [Abstract][Full Text] [Related]
4. The administration of erythropoietin attenuates kidney injury induced by ischemia/reperfusion with increased activation of Wnt/β-catenin signaling. Chen X; Wang CC; Song SM; Wei SY; Li JS; Zhao SL; Li B J Formos Med Assoc; 2015 May; 114(5):430-7. PubMed ID: 25682558 [TBL] [Abstract][Full Text] [Related]
10. Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Johnson DW; Pat B; Vesey DA; Guan Z; Endre Z; Gobe GC Kidney Int; 2006 May; 69(10):1806-13. PubMed ID: 16598197 [TBL] [Abstract][Full Text] [Related]
11. Effect of erythropoietin on mesenchymal stem cell differentiation and secretion in vitro in an acute kidney injury microenvironment. Liu NM; Tian J; Wang WW; Han GF; Cheng J; Huang J; Zhang JY Genet Mol Res; 2013 Feb; 12(4):6477-87. PubMed ID: 23479159 [TBL] [Abstract][Full Text] [Related]
12. Increased progression to kidney fibrosis after erythropoietin is used as a treatment for acute kidney injury. Gobe GC; Bennett NC; West M; Colditz P; Brown L; Vesey DA; Johnson DW Am J Physiol Renal Physiol; 2014 Mar; 306(6):F681-92. PubMed ID: 24402097 [TBL] [Abstract][Full Text] [Related]
13. Erythropoietin-mediated protection in kidney transplantation: nonerythropoietic EPO derivatives improve function without increasing risk of cardiovascular events. van Rijt WG; van Goor H; Ploeg RJ; Leuvenink HG Transpl Int; 2014 Mar; 27(3):241-8. PubMed ID: 23964738 [TBL] [Abstract][Full Text] [Related]
15. Erythropoietin pretreatment ameliorates renal ischaemia-reperfusion injury by activating PI3K/Akt signalling. Zhang J; Zou YR; Zhong X; Deng HD; Pu L; Peng K; Wang L Nephrology (Carlton); 2015 Apr; 20(4):266-72. PubMed ID: 25581532 [TBL] [Abstract][Full Text] [Related]
16. Erythropoietin ameliorates renal ischemia and reperfusion injury via inhibiting tubulointerstitial inflammation. Hu L; Yang C; Zhao T; Xu M; Tang Q; Yang B; Rong R; Zhu T J Surg Res; 2012 Jul; 176(1):260-6. PubMed ID: 21816412 [TBL] [Abstract][Full Text] [Related]
17. Post-treatment effects of erythropoietin and nordihydroguaiaretic acid on recovery from cisplatin-induced acute renal failure in the rat. Lee DW; Kwak IS; Lee SB; Song SH; Seong EY; Yang BY; Lee MY; Sol MY J Korean Med Sci; 2009 Jan; 24 Suppl(Suppl 1):S170-5. PubMed ID: 19194548 [TBL] [Abstract][Full Text] [Related]
18. Erythropoietin administration is associated with short-term improvement in glomerular filtration rate after ischemia-reperfusion injury. Sølling C; Christensen AT; Krag S; Frøkiaer J; Wogensen L; Krog J; Tønnesen EK Acta Anaesthesiol Scand; 2011 Feb; 55(2):185-95. PubMed ID: 21226860 [TBL] [Abstract][Full Text] [Related]
19. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. Sharples EJ; Patel N; Brown P; Stewart K; Mota-Philipe H; Sheaff M; Kieswich J; Allen D; Harwood S; Raftery M; Thiemermann C; Yaqoob MM J Am Soc Nephrol; 2004 Aug; 15(8):2115-24. PubMed ID: 15284297 [TBL] [Abstract][Full Text] [Related]
20. EPO and alpha-MSH prevent ischemia/reperfusion-induced down-regulation of AQPs and sodium transporters in rat kidney. Gong H; Wang W; Kwon TH; Jonassen T; Li C; Ring T; FrøkiAEr J; Nielsen S Kidney Int; 2004 Aug; 66(2):683-95. PubMed ID: 15253723 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]